Please assess the completion status of the following clinical trial:

Trial Title: A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Advanced Stage IIIB or IV non-small-cell lung cancer (NSCLC)~* Eastern Oncology Cooperative Group (ECOG) Performance Status 0 or 1~* Prior therapy defined as 1 prior systemic therapy for advanced disease~* Documented disease progression during or following most first line therapy for advanced disease~* Adequate hematologic, hepatic, renal function~Exclusion Criteria:~* Epidermal growth factor receptor (EGFR) mutations~* Anaplastic lymphoma kinase (ALK) translocations~* Predominantly squamous, adenosquamous or unclear histologic type~* Active or untreated central nervous system (CNS) metastases~* Active malignancies other than NSCLC within the last 5 years with the exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri or basal or squamous cell carcinoma of the skin~* Serious cardiac illness or medical conditions~* Pregnant or lactating women~* Uncontrolled intercurrent illness

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ganetespib and Docetaxel (Type: EXPERIMENTAL): Ganetespib (150 mg/m\^2) and docetaxel (75 mg/m\^2) were administered as separate 1-hour IV infusions on Day 1 of each 3-week treatment cycle. Administration of ganetespib preceded the administration of docetaxel. Ganetespib was administered again on Day 15 of each cycle.
- Docetaxel (Type: ACTIVE_COMPARATOR): Docetaxel (75 mg/m\^2) was administered on Day 1 of a 3-week treatment cycle by 1-hour IV infusion.

Based on this trial design, predict the completion outcome and termination type (if applicable).